Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?
Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NVO -7.78%) has seen revenue soar in recent years thanks to two drugs that have helped people around the world lose weight. The molecule is semaglutide, and it's sold under the name Ozempic for type 2 diabetes and Wegovy for weight loss -- but doctors have prescribed either for weight management.
Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging
Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through Orforglipron, potentially surpassing Novo Nordisk. Lilly's domestic capacity could provide it an edge against Denmark-based NVO, although supply chain risks imputed to tariffs cannot be downplayed.
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
More than 2 out of 5 American adults are obese, according to the Centers for Disease Control. With this figure in mind, it's no wonder Wall Street investment banks are telling anyone who will listen that sales of anti-obesity drugs could soar.
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Where Will Eli Lilly Be in 5 Years?
What a difference five years can make. Just look at Eli Lilly (LLY 14.56%).
Here's Why Eli Lilly (NYSE: LLY). Fidelity National (NYSE: FIS) and Diamondback Energy (Nasdaq: FANG) Are Soaring Today
The Dow Jones Industrial Average is tumbling by another 440 points in midday trading today, as President Trump criticized Federal Reserve chairman Jerome Powell's position, but the fact he is not trying to fire him heartened enough investors that the S&P 500 has bounced back into positive territory.
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.
